Association between SCN1A polymorphism rs3812718 and valproic acid resistance in epilepsy children: a case–control study and meta-analysis

Zhi Jian Wang, Jie Chen, Hai Liang Chen, Lin Yan Zhang, Duo Xu and Wen Ting Jiang

Department of Neurology, Fuzhou Neuropsychiatry Hospital, Fujian 350008, China

Correspondence: Jie Chen (974169478@qq.com)

Resistance to valproic acid (VPA), a first-line antiepileptic drug (AED), is occurring at an alarming rate, particularly in children. Signal nucleotide polymorphisms are considered crucial in this process. Therefore, we investigated whether the SCN1A polymorphism rs3812718 could be associated with VPA resistance. A total of 231 children with epilepsy who were solely administered VPA were enrolled. DNA was extracted from the peripheral blood samples and was genotyped by the Mass Array method. Furthermore, a meta-analysis was conducted between the drug responsive and resistant patients who were exposed to voltage-gated sodium channels. Results revealed that the TT genotype was associated with a higher risk of developing drug resistance (OR = 2.636, 95% CI 1.08–6.433, P = 0.033). After adjusting for the risk factors, a significant difference was still observed between the responsive and resistant groups (OR = 2.861, 95% CI 1.141–7.174, P = 0.025). Moreover, the recessive model was associated with a decreased drug resistance (OR = 0.402, 95% CI 0.167–0.968, P = 0.042) after correcting the risk factors. Meta-analysis of nine studies revealed similar results. In conclusion, our results proved that the rs3812718 TT genotype was associated with a high risk of developing drug resistance, and the recessive model could decrease the risk of VPA resistance.

Introduction

Resistance to antiepileptic drugs (AEDs) is crucial in epilepsy treatment. About 50–60% patients can be effectively treated by a single AED, the remaining being resistant to the treatment [1]. Genetic polymorphisms are assumed to be a crucial source of interindividual differences in the pharmacokinetics of AED efficacy. Thus, evaluating the genetic factors that influence the pharmacokinetics of AEDs may help in improving individualized therapies [2].

Single nucleotide polymorphisms (SNPs) are reported to be associated with AED resistance, in particular, by blocking the voltage-gated sodium (Na⁺) channels [3,4]. The Na⁺ channel neuronal type I alpha subunit (SCN1A), which encodes the α-subunit of the Nav1.1 Na⁺ channel, is presumed to be associated with AED resistance. An SCN1A functional polymorphism (IVS5-91 rs3812718 C > T) located in the 5′ splice donor site was reported to generate alternative splicing products, resulting in altered proportions of exon 5′ transcripts in the neonate and adult brain tissue [5].

Existing evidence has demonstrated that the rs3812718 polymorphism can affect the carbamazepine (CBZ) and coadministered valproic acid (VPA) resistance epilepsy in a cross-sectional study of Japanese patients [6]. Tate et al. reported that patients with the SCN1A rs3812718 AA genotype showed reduced sensitivity to the Na⁺ channel-blocking drugs [7]. However, studies evaluating the genomic variants that influence the VPA dosage, specifically in children, are scarce [6,8].
VPA, a fatty acid with an anticonvulsant property for treating several epilepsies and seizures, is prescribed worldwide as an effective and economic first-line AED [2]. Nevertheless, it is reported that the mean efficacy of VPA ranged from 70% to 76% [9]. VPA blocks the voltage-gated Na⁺ channels; therefore, we speculated that the SCN1A genotype polymorphism may also be associated with a reduced therapeutic effect of VPA by altering the response of the Na⁺ channel [10]. The present study assessed the association between the rs3812718 polymorphism and VPA resistance in pediatric epilepsies, followed by a meta-analysis to evaluate the relationship of the polymorphism with AED resistance.

Materials and methods

Patients recruitment

Patients were consecutively enrolled between February and October 2017 from the outpatient and inpatient department of Fuzhou Neuropsychiatry Hospital. The inclusion criteria were: (1) patients aged 2–18 years with epilepsy [11]; (2) those receiving sustained-release tablets of VPA twice a day for at least 30 days; (3) those who received a VPA monotherapy; and (4) patients without other severe diseases. Exclusion criteria were: (1) patients with significant mental disorders; severe liver, renal, or cardiac impairment; and serious adverse drug reactions to VPA and (2) patients with Dravet or generalized epilepsy with febrile seizure plus. Informed consents were obtained from all patients or from their immediate relatives. The present study was approved by the Ethics Committee of Fuzhou Neuropsychiatry Hospital and all the researches were performed in accordance with the Declaration of Helsinki.

On enrollment, the patients provided their clinical history including the demographic data, dosage regimens, and seizure type and frequency (before drug intake and after 1-year of treatment). A 1-year follow-up was done to evaluate the therapeutic effect of VPA. Steady-state venous blood samples were collected after the regular intake of sustained-release VPA tablets twice a day for at least 30 days. VPA-resistant epilepsy was defined as a reduced percentage of seizure frequency (less than or equal to 50%) and reduced seizure frequency (more than 50% was regarded as responsive epilepsy) [12–14]. The seizures and epilepsy syndromes were classified according to the International League Against Epilepsy (ILAE) [15,16].

Genotyping

Blood samples of all participants were collected and stored at −80°C until use. Genomic DNA was extracted from the whole blood using a commercial kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Patients’ DNA was purified by Qiagen DNA purification kit (Qiagen, Hilden, Germany). Genotyping was identified by MassArray method (Sequenom, USA).

Meta-analysis

Studies published by 20 May, 2018 were identified by a systematic literature search in PubMed, Embase, Web of Knowledge, China National Knowledge Infrastructure (CNKI) and WanFang Data. MeSH and title/abstract were used for all eligible studies that mainly focus on the genotype of rs3812718 polymorphism either in VPA responsive or resistant patients. The search strategy was as follows: ('seizure' or 'epilepsy') AND ('sodium channel neuronal type I alpha subunit' or 'SCN1A' or 'rs3812718') AND ('resistant*' or 'respons*').

Eligible studies must met the following criteria: (1) the study evaluated the association between rs3812718 polymorphism and AED resistant, (2) the report focused on detailed genotype frequencies among human beings, and (3) the investigation was a case–control study. Accordingly, the exclusion criteria were as follows: (1) studies without detailed genotype data; and (2) reports with overlapping data. The ‘Search strategy’ was shown in Supplement Materials.

Statistical analysis

All statistical analyses were performed by SPSS (version 17.0, SPSS Inc., Chicago, USA). Hardy–Weinberg equilibrium (HWE) was assessed by using a χ² test and a P value <0.05 was considered significant disequilibrium. Differences in genotypic frequencies between groups were calculated by the Pearson’s chi-square test or Mann–Whitney U test. Odds ratios (ORs) with 95% CI were calculated. Logistic regression analysis was used to evaluate the contribution of genetic and non-genetic factors to the VPA resistant under dominant and recessive model. Patients’s age, body weight and seizure frequency were treated as risk factors to be adjusted in the analysis.

For meta-analysis, the OR and 95% confidence interval (95% CI) were calculated to assess the relationship of rs3812718 polymorphism between AEDs responsive and resistant. Pooled ORs were obtained from combination of
Table 1 The basic characteristic of the enrolled patients

| Character       | Total | Response | Resistant | \( P \) |
|-----------------|-------|----------|-----------|--------|
| \( N \) (female)| 231 (94) | 185 (76) | 46 (18)   | 0.984  |
| Age             | 9.80 ± 5.1 | 9.03 ± 4.08 | 7.52 ± 4.1 | 0.057  |
| Body weight     | 33.48 ± 16.2 | 34.36 ± 15.43 | 29.74 ± 13.76 | 0.054  |
| Seizure type\(^a\) | 1.61 ± 4.45 | 1.4 ± 4.58 | 2.54 ± 3.77 | 0.855  |
| 1               | 142     | 117      | 25        |        |
| 2               | 62      | 49       | 13        |        |
| 3               | 27      | 19       | 8         |        |
| Frequency\(^b\) |         |          |           | 0.001  |
| <1              | 143     | 125      | 18        |        |
| 1–5             | 72      | 49       | 23        |        |
| >5              | 16      | 11       | 5         |        |
| Genotype        |         |          |           | 0.014  |
| CC              | 60      | 49       | 11        |        |
| CT              | 106     | 78       | 28        |        |
| TT              | 62      | 58       | 4         |        |

\(^a\)Seizure type: 1 represents general, 2 represents focal, and 3 represents unknown.
\(^b\)Seizure frequency before treatment (times per day).

Results

The characteristic of the study

A total of 231 (84 female) patients with a mean age of 9.80 ± 5.1 years and body weight 33.48 ± 16.2 kg were enrolled in the study. All patients were Chinese with confirmed epileptic diagnosis. Of these, 142 patients were classified as general type, 62 as focal type, and 27 as unable to be classified. The seizure frequency was less than once per day in 143 patients, between one and five times per day in 72 patients, and over five times per day in 16 patients. All participants were divided into two groups, VPA responsive (\( n = 185 \)) and VPA resistant (\( n = 46 \)). The demographics characteristics are listed in Table 1.

Genetics association analysis

The genotypes of CC, CT, and TT were present in 25%, 48%, and 27% patients, respectively. The MAF (major allele frequency) of rs3812718 polymorphism was 0.4879. Deviation from the Hardy–Weinberg equilibrium was not observed (\( P > 0.05 \)). The genotype distribution is listed in Table 2.

A genotype–phenotype correlation analysis between the SNP and VPA was performed. We found that the TT allele significantly correlated with the VPA resistant group (OR = 2.636, 95% CI 1.08–6.433, \( P = 0.033 \)). Significant differences were still observed between the responsive and resistant groups (OR = 2.861, 95% CI 1.141–7.174, \( P = 0.025 \)) even after adjusting the age, body weight, and seizure frequency (Table 3). In addition, the influence of genetic models (dominant and recessive model) on the VPA effect was also observed among the responsive and resistant groups. We did not find any significant associations in the recessive model (OR = 0.424, 95% CI 0.179–1.003, \( P = 0.051 \)). However, after adjusting the age, body weight, and seizure frequency, a significant difference was observed between the two groups (OR = 0.402, 95% CI 0.16–0.968, \( P = 0.042 \); Table 4).

Considering that the most significant association was observed with the recessive model, we further evaluated the relationship of genotype with VPA resistance by Poisson regression. The recessive model revealed a decreased risk of VPA resistance (OR = 0.688, 95% CI: 0.632–0.749). Meanwhile, the TT genotype with any clinical parameters was also analyzed, and no significant differences were observed between the patients carrying the TT genotype and those carrying the other two genotypes.
Table 2 The clinical parameters of all the patients according to SCN1A rs3812718 genotype

|            | CC     | CT     | TT     | TT vs. CT + CC |
|------------|--------|--------|--------|---------------|
| N (female) | 60 (33)| 106 (69)| 65 (26)| 0.338         |
| Ages       | 8.39 ± 3.7| 9.41 ± 4.18| 8.09 ± 4.22| 0.101         |
| Body weight| 31.72 ± 14.04| 34 ± 15.54| 30.47 ± 15.57| 0.113         |
| Frequencya | 1.41 ± 2.79| 2.08 ± 5.88| 0.96 ± 2.01| 0.484         |
| <1         | 39     | 68     | 46     |               |
| 1–5        | 17     | 39     | 16     |               |
| ≥5         | 4      | 9      | 3      |               |
| Seizure typeb |        |        |        | 0.508         |
| 1          | 28     | 81     | 43     |               |
| 2          | 21     | 285    | 16     |               |
| 3          | 11     | 10     | 6      |               |

aSeizure frequency before treatment (times per day).
bSeizure type: 1 represents general, 2 represents focal, and 3 represents unknown.

Table 3 The logistic regression analysis of rs3812718 SNP genotype with the drug resistant

| rs3812718 | OR      | 95% CI    | P   | OR#     | 95% CI#  | P#  |
|-----------|---------|-----------|-----|---------|----------|-----|
| CC Reference | 1.00    | 1.00-1.00 | 1   | 1.00    | 1.00-1.00 | 1   |
| CT        | 1.86    | 0.67-5.164| 0.234| 1.927   | 0.687-5.401| 0.212|
| TT        | 2.636   | 1.08-6.433| 0.033| 2.861   | 1.141-7.174| 0.025|

Note: # were adjusted for age, body weight and seizure frequency. Significant associations are marked in bold.

Table 4 The logistic regression analysis of the dominant model and recessive model in VPA response group and resistant group

| rs3812718 | OR      | 95% CI    | P   | OR#     | 95% CI#  | P#  |
|-----------|---------|-----------|-----|---------|----------|-----|
| Dominant model | 1.068   | 0.504-2.262| 0.864| 1.067   | 0.499-2.281| 0.867|
| Recessive model | 0.424   | 0.179-1.003| 0.051| 0.402   | 0.167-0.968| 0.042|

Note: # were adjusted for age, body weight and seizure frequency. Significant associations are marked in bold.

Meta-analysis results
The study characteristics included in this meta-analysis are listed in Table 5. No significant publication bias was found in the Begg’s test (P > 0.05). A sensitivity analysis was conducted to assess the influence of each individual study on the pooled OR. The results revealed that no single study influenced the quality of the pooled ORs in the sensitivity analyses.

A pooled meta-analysis was also employed to observe the Na+ channel AEDS and its effect on epilepsy. Our results revealed that the recessive model can significantly decrease the risk of drug resistance (P = 0.037, OR = 0.9, 95% CI: 0.82–0.99) by using a fixed model. Subgroup analysis indicated the significant association of the rs3812718 polymorphism with drug resistance in the Asian population (P = 0.016, OR = 0.87, 95% CI: 0.78–0.98), but not in the Caucasian population (P = 0.906, OR = 0.99, 95% CI: 0.82–1.19; Figures 1 and 2). Nevertheless, we did not find any correlation between the rs3812718 polymorphism and drug resistance in other genetic models (dominant model, allelic model, heterozygous model, and homozygous model; the forest plot can be found in supplement materials).

Discussion
Epilepsy is a common pediatric neurological disorder, with its prevalence ranging from 3000 to 6000 per million [19]. Administering AEDs is the core approach to control epileptic seizures; however, about 40% of patients still do not exhibit a satisfactory effect [20]. Approximately, 10–20% children develop drug-refractory epilepsy, with unclear etiologies [21]. Tate et al. reported that a common polymorphism in the SCN1A gene associates with the phenytoin serum levels during the maintenance dose [22]. Sánchez et al. reported that patients with symptomatic epilepsies with
Table 5 Characteristics of individual studies included in the meta-analysis

| Study                           | Ethnic       | Age Responsive | Age Resistant | Gender Responsive (M/F) | Gender Resistant (M/F) | Populations | Drugs responsive | Drugs resistant | Methods            |
|---------------------------------|--------------|----------------|---------------|-------------------------|------------------------|-------------|------------------|------------------|--------------------|
| Angelopoulou et al. [29]        | Greece       | 40.76 ± 16.55  | 43.56 ± 16.37 | 62/68                   | 37/33                  | 130         | 70               | TaqMan assay      |
| Boting Zhou et al. [28]         | Chinese      | N/A            | N/A           | N/A                     | N/A                    | N/A         | N/A              | Illumina Sequencing|
| Luo Zhou et al. [30]            | Chinese      | 22.36 ± 14.10  | 22.98 ± 11.21 | 144/91                  | 103/53                 | 235         | 156              | Illumina Sequencing|
| Patrick Kwana et al. [31]       | Chinese      | N/A            | N/A           | N/A                     | N/A                    | 272         | 199              | RT-PCR            |
| Yuze Cao et al. [32]            | Chinese      | 18.2 ± 16.8    | 19.0 ± 9.8    | 162                     | 136                    | 273         | 207              | Illumina Sequencing|
| Blanca et al. [23]              | Spanish      | 26.0 ± 19.8    | 27.0 ± 18.5   | 88/90                   | 56/55                  | 178         | 111              | TaqMan assay      |
| R. Kumari et al [33]            | India        | N/A            | N/A           | N/A                     | N/A                    | 124         | 89               | Real Time PCR     |
| Ida Manna et al. [34]           | Italy        | N/A            | N/A           | N/A                     | N/A                    | 401         | 482              | Real Time PCR     |
| Wang et al.                     | Chinese      | 9.13 ± 4.01    | 7.79 ± 4.01   | 144/85                  | 38/22                  | 229         | 60               | MassArray         |
| Haerian BS et al. [35]          | Malay        | 28 ± 15        | 30 ± 15       | 70/56                   | 64/61                  | 126         | 125              | MassArray         |
| Haerian BS et al. [30]          | India        | 30 ± 16        | 33 ± 17       | 49/43                   | 38/32                  | 92          | 70               | MassArra          |
| Haerian BS et al. [30]          | Chinese      | 34 ± 19        | 33 ± 17       | 83/65                   | 77/63                  | 148         | 140              | MassArra          |
| Haerian BS et al. [30]          | Chinese      | 38 ± 16        | 38 ± 14       | 180/156                 | 225/242                | 336         | 467              | MassArray         |

Figure 1. The forest plot of the SCN1A rs3812718 between drug resistant and responsive group under recessive model
The evaluation of the publication bias under recessive model

A is the Begg’s funnel plot. B is the sensitivity analysis.

Figure 2. The evaluation of the publication bias under recessive model

the ABCB1 3435 CT or TT genotypes revealed a lower risk of drug resistance than those with the CC genotype [23]. Despite discovering the majority of susceptibility polymorphism, the relation between the SNP and drug-resistant epilepsy remains unclear.

Drugs affecting the voltage-gated Na+ channels were most frequently used in treating epilepsy. VPA, with a mechanism of blocking the Na+ channel, remains the first choice for children with focal or generalized epilepsy. Although it can be used for treating several epilepsies and seizures, its association with the SCN1A rs3812718 polymorphism remained unclear. In the present study, we found that patients with the TT genotype easily developed drug resistance. Using the recessive model (TT vs. CT + CC), we found a significant correlation between the maximum doses of AEDs and carriers of the C allele (C/T or C/C genotype). Our results were partially consistent with the findings of Kazuko Nakagawa et al. [6], which were further proved by our meta-analysis results from 9 relative studies.

VPA emerges with a broad-spectrum efficacy range, which considerably varies among patients consuming the same dose of VPA. Although VPA therapy is relatively safe, epilepsy control with VPA can be a difficult and lengthy process owing to the drug’s narrow therapeutic index [24]. In addition, adverse drug reactions, particularly liver toxicity in young children, are also relatively common and often require dose adjustment [25]. Gene polymorphisms such as rs3812718 G > A may be related to toxic reactions and idiosyncratic adverse effects, which may explain the underlying mechanisms and possible prevention of drug resistance.

Mutations in Na+ channel transcripts in human epilepsy have been discovered in the brain tissue. Genetic variants from ion channels and functionally related genes may affect the response to first-line AEDs; thus, identifying genetic markers in the treatment response has been an urgent need in epilepsy therapeutics [26,27]. SCN1A rs3812718 polymorphism has been attributed to be a possible modifying factor for epilepsy therapeutics, particularly in the Asian populations. Zhou et al. reported that the polymorphism is significantly associated with the retention rate of CBZ monotherapy in a Chinese Han population [28]. Nevertheless, results from the replication studies have been inconsistent, with few negative results as well. Sánchez et al. reported no significant correlations between the SCN1A rs3812718 polymorphism and drug resistance in a Caucasian population [23].

This is the first study to report the significant association of SCN1A polymorphism (IVS5-91 rs3812718 C > T) with VPA resistance among children. Although our results are promising and may help in identifying patients with VPA resistance, these should be considered as preliminary results and further research is necessary. Moreover, the present study has certain limitations. First, the considerably complex mechanism of VPA and our focus solely on the Na+ channels fails to efficiently explain the drug resistance of VPA. Second, as the sample size was small, few indices in our research were nearly at the edge of the significance. Third, as fewer studies were available on the relationship between rs3812718 polymorphism and VPA resistance, we had to consider all the published articles that evaluated the effects of AEDs on the Na+ channel, eventually leading to diverse analyses.

In conclusion, our study had for the first time showed an association between the resistant and responsive of VPA and rs3812718 polymorphism. However, these data need to be replicated in a larger cohort of patients, and functional studies will be necessary to investigate whether and how rs3812718 polymorphism might influence key pathways involved in the pathogenesis of epilepsy and seizure.

**Funding**

This work was supported by Fuzhou science and technology plan (grant number: 2017-s-132-1).
Author contribution
Zhi Jian Wang designed the study and wrote the manuscript. Jie Chen designed the study and performed the literature searching. Hai Liang Chen and Lin Yan Zhang collected the blood samples and the information of patients. Duo Xu and Wen Ting Jiang did the meta-analysis. All authors reviewed and approved the manuscript.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
AED, antiepileptic drug; CBZ, carbamazepine; MAF, major allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism; VPA, valproic acid.

References
1 Brodie, M.J. (2016) Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. *Curr. Neurol. Neurosci. Rep.* **16**, 82, https://doi.org/10.1007/s11910-016-0678-x
2 Zhu, M.M., Li, H.L., Shi, L.H., Chen, X.P., Luo, J. and Zhang, Z.L. (2017) The pharmacogenomics of valproic acid. *J. Hum. Genet.* **62**, 1009–1014, https://doi.org/10.1038/jhg.2017.91
3 Abo, E.F.W., Abd, E.N.S., Habib, M.S., Alrefai, A.A. and Kasemry, Z.A. (2016) The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children. *Seizure* **41**, 75–80, https://doi.org/10.1016/j.seizure.2016.07.005
4 Thompson, C.H., Kahlig, K.M. and George, A.J. (2011) SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. *Epilepsia* **52**, 1000–1009, https://doi.org/10.1111/j.1528-1167.2011.03040.x
5 Heinen, Z.L., Yoon, W., Tate, S.K., Sen, A., Wood, N.W., Sisodiya, S.M. et al. (2007) Nov2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. *Am. J. Hum. Genet.* **80**, 876–883, https://doi.org/10.1086/516650
6 Abe, T., Kato, T., Ishitsu, T., Nakagawa, T., Hori, M. and Nakagawa, K. (2008) Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. *Br. J. Clin. Pharmacol.* **66**, 304–307, https://doi.org/10.1111/j.1365-2125.2008.03203.x
7 Tate, S.K., Depondt, C., Sisodiya, S.M., Cavalleri, G.L., Schorge, S., Soranzo, N. et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. *Proc. Natl. Acad. Sci. USA* **102**, 5507–5512, https://doi.org/10.1073/pnas.0407346102
8 Manna, I., Gambardella, A., Bianchi, A., Striano, P., Tozzi, R., Aguglia, U. et al. (2011) A functional polymorphism in the SCN1A gene does not influence phenytoin serum levels at maintenance dose. *Epilepsia* **52**, e40–e44, https://doi.org/10.1111/j.1528-1167.2011.03097.x
9 Fung, E.L. and Fung, B.B. (2017) Review and update of the Hong Kong Epilepsy Guideline on status epilepticus. *Hong Kong Med. J.* **23**, 67–73
10 Perucca, E. (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. *CNS Drugs* **16**, 695–714, https://doi.org/10.2165/00023210-200216100-00004
11 Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, C., Cross, J.H., Elger, C.E. et al. (2014) ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* **55**, 475–482, https://doi.org/10.1111/epi.12550
12 Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie, M.J., Allen, H.W., Mathern, G. et al. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* **51**, 1069–1077, https://doi.org/10.1111/j.1528-1167.2009.02397.x
13 Meng, H., Guo, G., Ren, J., Zhou, H., Ge, Y. and Guo, Y. (2011) Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. *Epilepsy Behav.* **21**, 27–30, https://doi.org/10.1016/j.yebeh.2011.02.015
14 Shahwan, A., Murphy, K., Doherty, C., Cavalleri, G.L., Muckian, C., Dicker, P. et al. (2007) The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. *Epilepsy Res.* **73**, 192–198, https://doi.org/10.1016/j.eplepsyres.2006.10.004
15 Okamoto, K., Fukuda, M., Saito, I., Horuchi, I., Okazawa, T. and Ishii, E. (2018) Incidence of childhood epilepsy: a population-based study in rural Japan. *Brain Dev.* **40**, 904–908, https://doi.org/10.1016/j.braindev.2018.06.003
16 Vaughan, K.A., Lopez, R.C., Buch, V.P., Mekary, R.A., Amundson, J.R., Shah, M. et al. (2018) An estimation of global volume of surgically treatable epilepsy based on a systematic review and meta-analysis of epilepsy. *J. Neurosurg.* **1–15, https://doi.org/10.3171/2018.3.JNS171722
17 Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guilhoto, L. et al. (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia* **58**, 512–521, https://doi.org/10.1111/epi.13709
18 Wei, H.X., Tian, G.X., Song, J.K., Yang, L.J. and Wang, Y.P. (2018) The association between rs16917496 T/C polymorphism of SET8 gene and cancer risk in Asian populations: a meta-analysis. *Biosci. Rep., https://doi.org/10.1042/BSR20180702
19 Ortega-Moreno, L., Giraldez, B.G., Soto-Insa, V., Losa-Ada, P.R., Rodrigo-Moreno, M., Alarcon-Morcillo, C. et al. (2017) Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. *PLoS One* **12**, e0188978, https://doi.org/10.1371/journal.pone.0188978
20 Riddold, L., Wojewodzka, G., Robinson, E., Landau, S., Noble, A., Taylor, S. et al. (2017) Characteristics associated with quality of life among people with drug-resistant epilepsy. *J. Neurol.* **264**, 1174–1184, https://doi.org/10.1007/s00415-017-8512-1
21 Anjea, S. and Jain, P. (2014) Refractory epilepsy in children. *Indian J. Pediatr.* **81**, 1063–1072, https://doi.org/10.1007/s12088-014-1533-1
22 Tate, S.K., Singh, R., Hung, C.C., Tai, J.J., Depondt, C., Cavalleri, G.L. et al. (2006) A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. *Pharmacogenet. Genomics* **16**, 721–726, https://doi.org/10.1097/01.fpc.0000230114.41828.73
23 Sanchez, M.B., Herranz, J.L., Leno, C., Arteaga, R., Oterino, A., Valdizan, E.M. et al. (2010) Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. *Seizure* 19, 93–101, https://doi.org/10.1016/j.seizure.2009.12.004
24 Nakashima, H., Oniki, K., Nishimura, M., Ogusu, N., Shimomasa, M., Ono, T. et al. (2015) Determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. *PLoS One* 10, e0141266, https://doi.org/10.1371/journal.pone.0141266
25 Rosati, A., De Masi, S. and Guerrini, R. (2015) Antiepileptic drug treatment in children with epilepsy. *CNS Drugs* 29, 847–863, https://doi.org/10.1007/s40263-015-0281-8
26 Monlong, J., Girard, S.L., Meloche, C., Cadieux-Dion, M., Andrade, D.M., Lafreniere, R.G. et al. (2018) Global characterization of copy number variants in epilepsy patients from whole genome sequencing. *PLoS Genet.* 14, https://doi.org/10.1371/journal.pgen.1007285
27 Orlandi, A., Paolino, M.C., Striano, P. and Parisi, P. (2018) Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. *Expert Opin. Drug Metab. Toxicol.* 14, 505–512, https://doi.org/10.1080/17425255.2018.1473377
28 Zhou, B.T., Zhou, Q.H., Yin, J.Y., Li, G.L., Xu, X.J., Qu, J. et al. (2012) Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. *Clin. Exp. Pharmacol. Physiol.* 39, 379–384, https://doi.org/10.1111/j.1440-1681.2012.05680.x
29 Angelopoulou, C., Veletza, S., Heliopoulos, I., Vadikolias, K., Tripsianis, G., Stathi, C. et al. (2017) Association of SCN1A gene polymorphism with antiepileptic drug responsiveness in the population of Thrace, Greece. *Arch. Med. Sci.* 13, 138–147, https://doi.org/10.5111/aoms.2016.59737
30 Zhou, L., Cao, Y., Long, H., Long, L., Xu, L., Liu, Z. et al. (2015) ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. *Pharmazie* 70, 416–420
31 Kwan, P., Poon, W.S., Ng, H.K., Kang, D.E., Wong, V., Ng, P.W. et al. (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. *Pharmacogenet. Genomics* 18, 989–998, https://doi.org/10.1097/FPC.0b013e3283117d67
32 Cao, Y.Z. (2013) Association study between the Polymorphisms of ABCB1,ABCC2,SCN1A,SCN2A,GABRA1 and Drug Resistant Epilepsy in Han Chinese, Central South University
33 Kumari, R., Lakhan, R., Kumar, S., Garg, R.K., Misra, U.K., Kalita, J. et al. (2013) SCN1AWSS-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. *Biochimie* 95, 1350–1353, https://doi.org/10.1016/j.biochi.2013.02.006
34 Manza, I., Gambardella, A., Bianchi, A., Striano, P., Tozzi, R., Aguglia, U. et al. (2011) A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. *Epilepsia* 52, e40–4, https://doi.org/10.1111/j.1528-1167.2011.03097.x
35 Haerian, B.S., Baum, L., Tan, H.J., Kwan, P., Raymond, A.A., Saruwatari, J. et al. (2012) SCN1A IVS5+5 polymorphism and response to sodium valproate: a multicenter study. *Pharmacogenomics* 13, 1477–1485, https://doi.org/10.2217/pgs.12.127